You don't have to be a great clinician to be a biotech CEO, but if you're not a great clinician, best you stay out of the lab.
Similarly, you don't have to be a great publicist to be a biotech CEO, but if you're not a great publicist, best you stay away from the cameras.
Try to understand the post before resorting to insults and dummy spits.
The idea of the Fishburne video and interviews like the Andrew Scott one are to attract investors and potential suitors. I've provided some objective material as to why LC's approach is less than ideal. No one should invest in a company without deeper research than an interview with the CEO, but a CEO that presents poorly may discourage an investor from doing the research in the first place (given the plethora of investment opportunities).
LC pro active investors interview, page-23
-
- There are more pages in this discussion • 44 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.7¢ |
Change
0.002(4.44%) |
Mkt cap ! $334.7M | |||
| Open | High | Low | Value | Volume |
| 4.5¢ | 4.7¢ | 4.5¢ | $441.9K | 9.592M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 816896 | 4.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.7¢ | 1286390 | 8 |
View Market Depth
| Last trade - 10.29am 08/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |